ARCH ONCOLOGY
Formerly Known as Vasculox. Arch Oncology is an immuno-oncology company developing anti-CD47 antibodies for the treatment of solid and hematologic cancers. The company's functionally diverse antibodies represent a new class of checkpoint inhibitors that harness both the adaptive and innate immune responses.
ARCH ONCOLOGY
Social Links:
Industry:
Biotechnology Medical Oncology Therapeutics
Founded:
2006-01-01
Address:
St Louis, Missouri, United States
Country:
United States
Website Url:
http://www.archoncology.com
Total Employee:
11+
Status:
Active
Contact:
(314)932-4032
Email Addresses:
[email protected]
Total Funding:
250.4 M USD
Technology used in webpage:
Euro SPF Google Maps Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS Cloudflare DNS GoDaddy
Similar Organizations
Accent Therapeutics
Accent Therapeutics is a biopharmaceutical company.
ArcherDX
ArcherDX is a biotechnology firm specializing in cancer research.
Avalo Therapeutics
Avalo Therapeutics is a clinical-stage biopharmaceutical company.
Avstera Therapeutics
Avstera Therapeutics is an oncology-focused biotech company that fulfil unmet needs of cancer patients.
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company.
Ocugen
Ocugen is a clinical stage biopharmaceutical company.
Peroxitech Therapeutics
Peroxitech Therapeutics operates as a biopharmaceutical company.
Spark Therapeutics
Spark Therapeutics is focused on the development of gene therapy.
Vittoria Biotherapeutics
Vittoria Biotherapeutics is a gene-edited cell therapeutics company.
Current Advisors List
Current Employees Featured
Founder
Investors List
Cowen Healthcare Investments
Cowen Healthcare Investments investment in Series C - Arch Oncology
Avego Healthcare Capital
Avego Healthcare Capital investment in Series C - Arch Oncology
Broadfin Capital
Broadfin Capital investment in Series C - Arch Oncology
Lightchain
Lightchain investment in Series C - Arch Oncology
3×5 Partners
3×5 Partners investment in Series C - Arch Oncology
RiverVest
RiverVest investment in Series C - Arch Oncology
FMB Research
FMB Research investment in Series C - Arch Oncology
Adage Capital Management
Adage Capital Management investment in Series C - Arch Oncology
Eventide
Eventide investment in Series C - Arch Oncology
Roche Venture Fund
Roche Venture Fund investment in Series C - Arch Oncology
Official Site Inspections
http://www.archoncology.com
- Host name: 106.233.71.198.host.secureserver.net
- IP address: 198.71.233.106
- Location: Scottsdale United States
- Latitude: 33.6013
- Longitude: -111.8867
- Metro Code: 753
- Timezone: America/Phoenix
- Postal: 85260
More informations about "Arch Oncology"
Arch Oncology - Crunchbase Company Profile & Funding
Arch Oncology is an immuno-oncology company developing anti-CD47 antibodies for the treatment of solid and hematologic cancers. The company's …See details»
Arch Oncology Company Profile | Management and Employees …
Arch Oncology Profile and History Arch Oncology, Inc. was founded in 2006 out of Brisbane, California, they are a privately-held, clinical-stage immuno-oncology company focused on the …See details»
Arch Oncology - Craft
Arch Oncology is a clinical-stage immuno-oncology company focused on the discovery and development of antibody therapies for the treatment of patients with cancer. The Company's …See details»
Arch Oncology: Contact Details and Business Profile
Arch Oncology, Inc. is a clinical-stage immuno-oncology company focused on the discovery and development of potential best-in-class antibody therapies for the treatment of patients with …See details»
Arch Oncology - Overview, News & Similar companies - ZoomInfo
May 22, 2021 Arch Oncology, Inc. was founded in 2006 out of Brisbane, California, they are a privately-held, clinical-stage immuno-oncology company focused on the discovery and …See details»
Arch Oncology 2025 Company Profile: Valuation, …
Arch Oncology General Information Description. Developer of second-generation antibodies designed for the treatment of solid tumors. The company's antibodies represent a new class of checkpoint inhibitors that bridge the innate and …See details»
Arch Oncology CEO and Key Executive Team | Craft.co
Arch Oncology's Chairman is John McKearn. Other executives include Daniel Pereira, Chief Scientific Officer; Arun Kashyap, Vice President, Research and 1 others. See the full …See details»
Arch Oncology - Company Profile - Tracxn
Feb 25, 2025 Arch Oncology Presents New Preclinical T-ALL Data on Highly-differentiated Anti-CD47 Antibody AO-176 at AACR 2021GlobeNewswire • Apr 10, 2021 • Arch Oncology Arch …See details»
Arch Oncology Overview | SignalHire Company Profile
The position of the President & CEO is occupied by Laurence Blumberg. Its headquarters is located at Brisbane, California, USA. The number of employees ranges from 25 to 100. The …See details»
Board of Directors - Team at Arch Oncology - The Org
Other teams at Arch Oncology. View all. Leadership Team. 3 members. CEO and Executive Team. 1 members. Discover similar companies. Dyno Therapeutics. Series A • Cambridge, …See details»
Orphanet: ARCH ONCOLOGY, INC.
ARCH ONCOLOGY, INC. Activity(ies) registered in Orphanet: Sponsor of orphan designation Phone 1: 1 415-671-4035 ARCH Oncology, Inc. ARCH Oncology, Inc. 2000 Sierra Point …See details»
Arch Oncology Company Overview, Contact Details & Competitors …
Apr 27, 2021 Learn more about Arch Oncology's company details, contact information, competitors, and more. Find accurate contact data easily with LeadIQ. Book a demo today. ...See details»
Arch Oncology - Contacts, Employees, Board Members
Arch Oncology is a venture-stage biopharmaceutical company. New. Resources. Advanced Search. Start Free Trial ... Experience the new Crunchbase, powered by AI . Experience the …See details»
Arch Oncology (USA) Funding: $250.4M - Medical Startups
Arch Oncology is aiming high to discover and develop new antibody therapeutics to treat patients living with cancer. It's committed to advancing antibodies with best-in-class potential. …See details»
BioGenerator Company Arch Oncology Closes $105M Series C …
Arch Oncology, Inc. is a privately-held, clinical-stage immuno-oncology company focused on the discovery and development of potential best-in-class biologic therapies for the treatment of …See details»
Arch Oncology Appoints Laurence Blumberg, M.D. President and …
Apr 7, 2021 BRISBANE, Calif. and ST. LOUIS, April 07, 2021 (GLOBE NEWSWIRE) -- Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and …See details»
Arch Oncology, Inc.
Earlier, Dr. Cherrington served as CEO of QUE Oncology, and as President and CEO of Arch Oncology, Revitope Oncology, Inc., Zenith Epigenetics, and Pathway Therapeutics. Dr. …See details»
Roche-backed Arch Oncology gets off $50M round for anti-CD47 …
Mar 25, 2019 This latest financing included Arch Oncology’s existing investors, RiverVest Venture Partners, Roche Venture Fund and 3x5 Partners, and was led by new investor …See details»
Arch Oncology, Inc. - Rivervest
Arch Oncology’s next-generation anti-CD47 antibodies are highly differentiated compared to other agents in this class, with the potential to improve significantly upon / PORTFOLIO St. Louis, …See details»
Arch Oncology Secures $105 Million Series C Financing
Apr 27, 2021 Arch Oncology’s existing investors, including Roche Venture Fund, RiverVest Venture Partners, and Lightchain, also participated in the round. In connection with the …See details»